

NAVIGATING A CHANGING LANDSCAPE IN TNBC

PHARMACIST-FOCUSED STRATEGIES IN THE ERA OF IMMUNOTHERAPY

- Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. *Ann Oncol*. 2019;30(3):405–411.
- Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. *Ann Oncol*. 2019;30(3):397–404.
- Bell R, Brown J, Parmar M, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. *Ann Oncol*. 2017;28(4):754–760.
- Berghoff AS, Venur VA, Preusser M, et al. Immune checkpoint inhibitors in brain metastases: from biology to treatment. *Am Soc Clin Oncol Educ Book*. 2016;35:e116–e122.
- Bianchini G, Balko JM, Mayer IA, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. *Nat Rev Clin Oncol*. 2016;13(11):674–690.
- Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol*. 2018;36(17):1714–1768.
- Brufsky A, Kim SB, Zvirbule Z, et al. Phase II COLET study: atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC). Abstract 1013. Presented at: American Society of Clinical Oncology Annual Meeting; May 31–June 4, 2019; Chicago, Illinois.
- Castan JC, Guo Z, Karantza V, et al. KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). *Ann Oncol*. 2017;28(5):v68–v73.
- Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*. 2013;39(1):1–10.
- Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. *JAMA Oncol*. 2019;5(7):1049–1054.
- Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in *Lancet*. 2019;393(10175):986]. *Lancet*. 2014;384(9938):164–172.
- Crompton JG, Sukumar M, Roychoudhuri R, et al. AKT inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer Res*. 2015;75(2):296–305.
- Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. *Breast Cancer Res Treat*. 2018;167(3):671–686.
- Domchek SM, Postel-Vinay S, Im SA, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC). Abstract PD5-04. Presented at: San Antonio Breast Cancer Symposium; December 4–8, 2018; San Antonio, Texas.
- Domchek SM, Postel-Vinay S, Im SA, et al. Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): updated results in patients with germline BRCA-mutated metastatic breast cancer. *Ann Oncol*. 2019;30(5):v475–v532.
- Ebert PJR, Cheung J, Yang Y, et al. MAP kinase inhibition promotes t-cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. *Immunity*. 2016;44(3):609–621.
- El Majzoub I, Qdaisat A, Thein KZ, et al. Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. *Ann Emerg Med*. 2019;73(1):79–87.

NAVIGATING A CHANGING LANDSCAPE IN TNBC

PHARMACIST-FOCUSED STRATEGIES IN THE ERA OF IMMUNOTHERAPY

- Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. *JAMA Oncol.* 2019;5(1):74–82.
- Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. *Cancer Immunol Res.* 2015;3(5):436–443.
- Gatti V, Bongiorno-Borbone L, Fierro C, et al. p63 at the crossroads between stemness and metastasis in breast cancer. *Int J Mol Sci.* 2019;20(11):2683.
- George S, Miao D, Demetri GD, et al. Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. *Immunity.* 2017;46(2):197–204.
- Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer: NeoTRIPaPDL1 Michelangelo randomized study. Abstract GS3-04. Presented at: San Antonio Breast Cancer Symposium; December 10–14, 2019; San Antonio, Texas.
- Haanen JBAG, Carbone F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2017;28(suppl_4):iv119–iv142.
- Jia H, Truica CI, Wang B, et al. Immunotherapy for triple-negative breast cancer: existing challenges and exciting prospects. *Drug Resist Updat.* 2017;32:1–15.
- Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. *Cancer.* 2017;123(11):1904–1911.
- Kanz BA, Pollack MH, Johnpulle R, et al. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. *J Immunother Cancer.* 2016;4:60.
- Lebert JM, Lester R, Powell E, et al. Advances in the systemic treatment of triple-negative breast cancer. *Curr Oncol.* 2018;25(Suppl 1):S142–S150.
- Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. *PLoS One.* 2016;11(6):e0157368.
- Loi S, Schmid P, Cortes J, et al. Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial. Abstract P3-10-09. Presented at: San Antonio Breast Cancer Symposium; December 4–8, 2018; San Antonio, Texas.
- Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *J Clin Oncol.* 2013;31(7):860–867.
- Loibl S, Untch M, Burchardi N, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. *Ann Oncol.* 2019;30(8):1279–1288.
- Loibl S, Untch M, Burchardi N, et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer. Abstract 104. Presented at: American Society of Clinical Oncology Annual Meeting; June 3, 2018; Chicago, Illinois.
- Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. *Ann Oncol.* 2018;29(12):2341–2347.

NAVIGATING A CHANGING LANDSCAPE IN TNBC

PHARMACIST-FOCUSED STRATEGIES IN THE ERA OF IMMUNOTHERAPY

- Luen S, Virassamy B, Savas P, et al. The genomic landscape of breast cancer and its interaction with host immunity. *Breast*. 2016;29:241–250.
- Marra A, Viale G, Curigliano G. Recent advances in triple-negative breast cancer: the immunotherapy era. *BMC Med*. 2019;17(1):90.
- Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol*. 2017;28(2):368–376.
- Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. *Eur J Cancer*. 2016;54:139–148.
- Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer. *Cancer Immunol Res*. 2014;2(4):361–370.
- Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. *J Clin Oncol*. 2016;34(21):2460–2467.
- Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 Trial. *JAMA Oncol*. 2020. [Epub ahead of print].
- Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2. Abstract 506. Presented at: American Society of Clinical Oncology Annual Meeting; June 2–6, 2017; Chicago, Illinois.
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer. Version 3.2020; March 6, 2020. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed March 2020.
- National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: management of immunotherapy-related toxicities. Version 1.2020; December 16, 2019. NCCN website. https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Accessed March 2020.
- Nicolaidis NC, Chrousos GP, Charmandari E, et al. Adrenal insufficiency. In: *Endotext*. South Dartmouth, Massachusetts: MDText.com, Inc; 2000–2017.
- Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. *N Engl J Med*. 2018;378(2):158–168.
- Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. *N Engl J Med*. 2012;366(26):2438–2441.
- Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017;5(1):95.
- Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [published correction appears in *N Engl J Med*. 2017;377(17):1700]. *N Engl J Med*. 2017;377(6):523–533.
- Saha P, Nanda R. Concepts and targets in triple-negative breast cancer: recent results and clinical implications. *Ther Adv Med Oncol*. 2016;8(5):351–359.
- Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet*. 2019;51(2):202–206.

NAVIGATING A CHANGING LANDSCAPE IN TNBC

PHARMACIST-FOCUSED STRATEGIES IN THE ERA OF IMMUNOTHERAPY

- Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108–2121.
- Schmid P, Cortes J, Dent R, et al. Keynote-522: phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC). *Ann Oncol*. 2019;30(5):v851–v934.
- Schmid P, Loirat D, Savas P, et al. Phase Ib study evaluating a triplet combination of ipatasertib, atezolizumab, and paclitaxel or nab-paclitaxel as first line (1L) therapy for locally advanced/metastatic triple-negative breast cancer. Abstract CT049. Presented at: American Association of Cancer Research (AACR) Annual Meeting; March 29–April 3, 2019; Atlanta, Georgia.
- Schmid P, Park YH, Ferreira M, et al. KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery. Abstract GS3-03. Presented at: San Antonio Breast Cancer Symposium; December 10–14, 2019; San Antonio, Texas.
- Sikov WM, Barry DA, Perou CM, et al. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance). Abstract S2-05. Presented at: San Antonio Breast Cancer Symposium; December 8–12, 2015; San Antonio, Texas.
- Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. *J Clin Oncol*. 2017;35(10):1049–1060.
- Sznol M, Postow MA, Davies MJ, et al. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. *Cancer Treat Rev*. 2017;58:70–76.
- Tucker N. KEYNOTE-355 meets a coprimary endpoint for treatment of patients with mTNBC. Published February 12, 2020. Targeted Oncology website. <https://www.targetedonc.com/news/keynote355-meets-a-coprimary-endpoint-for-treatment-of-patients-with-mtnbc>. Accessed March 2020.
- U.S. National Library of Medicine. ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/>. Accessed March 2020.
- Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. *ESMO Open*. 2017;2(4):e000247.
- Vinayak S, Tolaney SM, Schwartzberg L, et al. Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162). Abstract PD5-02. Presented at: San Antonio Breast Cancer Symposium; December 4–8, 2018; San Antonio, Texas.
- von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. *N Engl J Med*. 2012;366(4):299–309.
- Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. *J Clin Oncol*. 2017;35(7):785–792.
- Weinstock C, Singh H, Maher VE, et al. FDA analysis of patients with baseline autoimmune diseases treated with PD-1/PD-L1 immunotherapy agents. Abstract 3018. Presented at: American Society of Clinical Oncology Annual Meeting; June 2–6, 2017; Chicago, Illinois.